Controlled Human Infection for Vaccination Against Streptococcus Pyogenes

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

September 28, 2019

Study Completion Date

April 21, 2020

Conditions
Streptococcus Pyogenes PharyngitisStreptococcus PharyngitisStrep ThroatStreptococcus Pyogenes InfectionGroup A Streptococcus: B Hemolytic PharyngitisGroup A Streptococcal InfectionGram-Positive Bacterial InfectionsBacterial Infections
Interventions
BIOLOGICAL

emm75 Streptococcus pyogenes (GAS M75, strain 611024)

Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.

Trial Locations (1)

3004

Centre for Clinical Studies (Nucleus Network Limited), Melbourne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Melbourne

OTHER

collaborator

Nucleus Network Ltd

OTHER

collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

Telethon Kids Institute

OTHER

collaborator

The Peter Doherty Institute for Infection and Immunity

OTHER

collaborator

Queen Fabiola Children's University Hospital

OTHER

collaborator

Griffith University

OTHER

collaborator

University of Wollongong

OTHER

collaborator

The University of Queensland

OTHER

collaborator

University of Auckland, New Zealand

OTHER

collaborator

University of Tennessee

OTHER

lead

Andrew Steer

OTHER

NCT03361163 - Controlled Human Infection for Vaccination Against Streptococcus Pyogenes | Biotech Hunter | Biotech Hunter